Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

G. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, Robert R. Recker, D. Felsenberg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4% [95% confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.

Original languageEnglish
Pages (from-to)1769-1778
Number of pages10
JournalOsteoporosis International
Volume23
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Postmenopausal Osteoporosis
Intravenous Administration
Bone Density
Spine
ibandronic acid
Confidence Intervals
Safety
Bone and Bones
Photon Absorptiometry
Therapeutics
Placebos
Maintenance

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis : 5-year data from the DIVA study long-term extension. / Bianchi, G.; Czerwinski, E.; Kenwright, A.; Burdeska, A.; Recker, Robert R.; Felsenberg, D.

In: Osteoporosis International, Vol. 23, No. 6, 06.2012, p. 1769-1778.

Research output: Contribution to journalArticle

@article{7c1479d23110430aab88bf7cd3daa92e,
title = "Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension",
abstract = "Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1{\%}) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75{\%} adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4{\%} [95{\%} confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1{\%} [95{\%} CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.",
author = "G. Bianchi and E. Czerwinski and A. Kenwright and A. Burdeska and Recker, {Robert R.} and D. Felsenberg",
year = "2012",
month = "6",
doi = "10.1007/s00198-011-1793-9",
language = "English",
volume = "23",
pages = "1769--1778",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "6",

}

TY - JOUR

T1 - Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis

T2 - 5-year data from the DIVA study long-term extension

AU - Bianchi, G.

AU - Czerwinski, E.

AU - Kenwright, A.

AU - Burdeska, A.

AU - Recker, Robert R.

AU - Felsenberg, D.

PY - 2012/6

Y1 - 2012/6

N2 - Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4% [95% confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.

AB - Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4% [95% confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84863617923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863617923&partnerID=8YFLogxK

U2 - 10.1007/s00198-011-1793-9

DO - 10.1007/s00198-011-1793-9

M3 - Article

C2 - 21975558

AN - SCOPUS:84863617923

VL - 23

SP - 1769

EP - 1778

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 6

ER -